Technically Speakin...
Health Care: Drugs
Hemispherx Biopharma Inc. (HEB: AMEX)
$0.27 0.00 | 0.00%
06/04/12 - 01:03 PM ET
Company Income Statement
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Sales | 161.00K | 135.00K | 111.00K | 265.00K |
| Cost of Sales | 413.00K | 561.00K | -397.00K | 82.00K |
| Gross Operating Profit | -252.00K | -426.00K | 508.00K | 183.00K |
| Selling, General, and Administrative Expenses | 6.69M | 7.57M | 5.80M | 6.48M |
| Research & Development | 6.72M | 7.61M | 7.00M | 5.80M |
| Operating Income before D & A (EBITDA) | -13.66M | -15.61M | -12.28M | -12.10M |
| Depreciation & Amortization | 630.00K | 780.00K | 981.00K | 716.00K |
| Interest Income | 624.00K | 2.38M | 67.00K | 592.00K |
| Other Income - Net | 4.70M | 879.00K | 0.00 | 0.00 |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -8.97M | -13.12M | -13.20M | -12.22M |
| Interest Expense | 41.00K | 11.00K | 241.00K | 0.00 |
| Pre-Tax Income | -9.02M | -13.14M | -13.44M | -12.22M |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -9.02M | -13.14M | -13.44M | -12.22M |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -9.02M | -13.14M | -13.44M | -12.22M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -9.02M | -13.14M | -13.44M | -12.22M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-9.02M | -13.14M | -13.44M | -12.22M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -9.02M | -13.14M | -13.44M | -12.22M |
| Basic EPS from Continuing Ops. | -0.07 | -0.10 | -0.12 | -0.16 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -0.07 | -0.10 | -0.12 | -0.16 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -0.07 | -0.10 | -0.12 | -0.16 |
| Basic Normalized Net Income/Share | -0.07 | -0.10 | -0.12 | -0.16 |
| EPS fr Continuing Ops. | -0.07 | -0.10 | -0.12 | -0.16 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -0.07 | -0.10 | -0.12 | -0.16 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -0.07 | -0.10 | -0.12 | -0.16 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-0.07 | -0.10 | -0.12 | -0.16 |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with HEB
- Portfolio NameUser Type
- Uservlady 1
- ContributorBarron's Insider Purchases ...
- ContributorBarron's Insider Purchases ...
- Usermaybe will work?
- UserTornado Portfolio
- Userjimb Portfolio 1
- Usergenomics
- User5for5
- Userjoe today
- UserNathan88
Latest HEB Headlines from TheStreet
- Hemisphrex Biopharma Announces Fiscal 2010 Year Results 03.29.11 | 01:03 pm
- Hemispherx Biopharma Reports On Annual Stockholder Meeting 03.22.11 | 02:03 pm
- Hemispherx Biopharma Announces 9th Clinical Investigators Conference: Ampligen Clinical Trials Highlighted 03.07.11 | 02:03 pm
- Chronix Biomedical And Hemispherx Biopharma Jointly File Patent Application For A Blood Test For Chronic Fatigue Syndrome (CFS) 03.03.11 | 10:03 am
- Hemispherx Biopharma Annual Meeting Set 02.24.11 | 08:02 am
- Hemispherx Biopharma, Inc. Announces It Has Scheduled Its 2010 Annual Stockholders' Meeting To Occur On March 17, 2011 In Remediation Of Notice From The NYSE Amex Of Non-Compliance With The Requirement To Hold Its Annual Stockholders' Meeting By The End Of 2010 02.23.11 | 01:02 pm
- Hemispherx Biopharma Appoints Senior Pharma Executive To Key Manufacturing Position 02.17.11 | 10:02 am
- Hemispherx Biopharma Announces US District Court Grants Final Approval Of Settlement Of Securities Class Actions 02.17.11 | 08:02 am
- FDA Authorizes Alferon LDO Clinical Study For Treatment And Prevention Of Influenza 01.04.11 | 10:01 am
- Hemispherx Biopharma, Inc. To Restate 2009 Financial Statements 12.28.10 | 04:12 pm
Press Releases for HEB
- Securities Class Action Filed By Shepherd, Finkelman, Miller & Shah, LLP On Behalf Of Hemispherx Biopharma Securities Purchasers Between February 18, 2009 And November 2, 2009 - PR Newswire 12.08.09 | 04:12 pm
Partner Headlines for HEB
- Oink Oink: Profit From The Return Of Swine Flu - Benzinga 01.12.12 | 01:01 pm
- UPDATE 1-Hemispherx awarded $188 mln in "illegal" takeover suit - Reuters 08.18.10 | 12:08 pm
